Drug firm Aurobindo Pharma today reported a 23.81 per cent rise in consolidated net profit to Rs 584.96 crore for the first quarter ended June 30, 2016, mainly on account of robust sales.
The company had posted a net profit after taxes, minority interest and share of profit of joint ventures of Rs 472.45 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a filing to BSE.
Consolidated total income from operations also rose to Rs 3,725.90 crore for the quarter under consideration as against Rs 3,298.93 crore for the same period a year ago.
Shares of Aurobindo Pharma today closed at Rs 736.30 per scrip on BSE, down 1.84 per cent from its previous close.
Commenting on the results, Aurobindo Pharma MD N Govindarajan, said: "The quarter started with a double digit growth year on year on the back of overall business performance. With focus on execution and capability enhancements we continue to progress on specialty generics for a sustained long term growth.
Disclaimer: No Business Standard Journalist was involved in creation of this content
